Searchable abstracts of presentations at key conferences on calcified tissues

Bone Abstracts

Published by BioScientifica
Volume 1 | ECTS2013 | Next issue

European Calcified Tissue Society Congress 2013

Lisbon, Portugal
18 May 2013 - 22 May 2013

Card image cap
European Calcified Tissue Society Congress 2013, 18 - 22 May 2013; Lisbon, Portugal

Poster Presentations

Osteoporosis: treatment

Previous section
Osteoporosis: pathophysiology and epidemiology
Table of contents
Next section
Other diseases of bone and mineral metabolism

ba0001pp390 | Osteoporosis: treatment

Abstract unavailable

ba0001pp391 | Osteoporosis: treatment

Electronic clinical decision support for the management of osteoporosis in primary care

ba0001pp392 | Osteoporosis: treatment

Anti-osteoporosis treatment amongst austrian hip fracture patients: status quo, and effects on mortality and subsequent fracture risk

ba0001pp393 | Osteoporosis: treatment

Remarkable bone mineral density increases on teriparatide in patients with glucocorticoid-induced osteoporosis and Crohn's disease

ba0001pp394 | Osteoporosis: treatment

Effects of a new conjugate drug in a rat model of postmenopausal osteoporosis

ba0001pp395 | Osteoporosis: treatment

Renal function and safety result after 1 year treatment of zoledronic acid in Chinese women with postmenopausal osteoporosis

ba0001pp396 | Osteoporosis: treatment

Characterization and risk factors of acute-phase response following a first-dose administration of zoledronic acid for treatment of osteoporosis

ba0001pp397 | Osteoporosis: treatment

Intact heparin inhibits BMP6 osteogenic activity

ba0001pp398 | Osteoporosis: treatment

Health economic consequences of fractures in patients with osteoporosis: a national register based study of total and incremental health costs following fracture

ba0001pp399 | Osteoporosis: treatment

Assessment of serum 25-hydroxyvitamin D concentrations in postmenopausal osteoporotic women: a retrospective study to evaluate long-term treatment with vitamin D3

ba0001pp400 | Osteoporosis: treatment

Osteonecrosis of the jaw and non-malignant disease

ba0001pp401 | Osteoporosis: treatment

Effectiveness of Strontium Renalate therapy for osteoporosis in men

ba0001pp402 | Osteoporosis: treatment

Do Bisphosphonates remain basic drugs for the treatment of osteoporosis?

ba0001pp403 | Osteoporosis: treatment

Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis

ba0001pp404 | Osteoporosis: treatment

Sequential therapy after PTH 1–84 treatment: comparison among bisphosphonates and strontium ranelate

ba0001pp405 | Osteoporosis: treatment

Adherence to therapy: outcomes after seven years of treatment with bisphosphonates

ba0001pp406 | Osteoporosis: treatment

In real clinical practice osteoporosis drugs are taken for a very short period: analysis of persistence in the campania region

ba0001pp407 | Osteoporosis: treatment

Effect of a mixture of calcium, vitamin D, inulin and soy isoflavones on bone metabolism in post-menopausal women: a retrospective analysis

ba0001pp408 | Osteoporosis: treatment

Vertebroplasty vs kyphoplasty in osteoporotic vertebral fractures: a finite element comparative analysis

ba0001pp409 | Osteoporosis: treatment

25-OH vitamin D and γ-δ TCR lymphocyte interplay in the pathogenesis of acute phase reaction after zoledronic acid infusion for osteoporosis treatment

ba0001pp410 | Osteoporosis: treatment

Bone turnover markers and radiographic progression of vertebral compression fractures during anti-osteoporotic therapy

ba0001pp411 | Osteoporosis: treatment

Changes in low back pain and upper gastrointestinal symptoms in Japanese osteoporotic patients after switching to once-monthly oral minodronate from daily or weekly bisphosphonates

ba0001pp412 | Osteoporosis: treatment

Preoperative bisphosphonate treatment in patients with neuromuscular scoliosis improves bone strength of vertebral body

ba0001pp413 | Osteoporosis: treatment

Early response to once-monthly oral minodronate after switching from daily or weekly bisphosphonates in Japanese osteoporotic patients

ba0001pp414 | Osteoporosis: treatment

Treatment with eldecalcitol (ED-71) and raloxifene combined increases cancellous and cortical bone strength in ovariectomized rats

ba0001pp415 | Osteoporosis: treatment

Patient preference and adherence to once-monthly oral minodronate in Japanese osteoporotic patients previously using daily or weekly bisphosphonates

ba0001pp416 | Osteoporosis: treatment

Meta-analysis of the effects of vitamin D supplements on bone mineral density in adults

ba0001pp417 | Osteoporosis: treatment

A case of atypical femoral fracture with abnormal cortical bone characterized by impaired mineralization and pyrophosphate accumulation

ba0001pp418 | Osteoporosis: treatment

Myricetin suppress LPS-induced MMP expression in human periodontal ligament fibroblasts and inhibit osteoclastogenesis by downregulating NFATc1 in LPS-induced RAW 264.7 cells

ba0001pp419 | Osteoporosis: treatment

Analysis of clinical assessment and efficacy of once-yearly i.v. zoledronic acid for osteoporosis

ba0001pp420 | Osteoporosis: treatment

Subsequent hip fracture in Inchon and Bucheon area of Korea (Cohort study)

ba0001pp421 | Osteoporosis: treatment

The efficiency of bisphosphonates (alendronate, risedronate, ibandronate) for postmenopausal osteoporosis after 1 year of therapy

ba0001pp422 | Osteoporosis: treatment

Bisphosphonates poisonous action

ba0001pp423 | Osteoporosis: treatment

Three years' experience of zoledronic acid use in the treatment of postmenopausal osteoporosis

ba0001pp424 | Osteoporosis: treatment

Acute phase response and zoledronic acid therapy

ba0001pp425 | Osteoporosis: treatment

Evaluation with densitometry of patients with breast cancer and low bone mineral density after 2 years of treatment

ba0001pp426 | Osteoporosis: treatment

Characterization and incidence on acute phase reaction in Paget's disease after zoledronic acid infusion

ba0001pp427 | Osteoporosis: treatment

Risk factors for the development of vertebral fractures after percutaneous vertebroplasty

ba0001pp428 | Osteoporosis: treatment

Persistence with different anti-osteoporosis medications: a population-based cohort study.

ba0001pp429 | Osteoporosis: treatment

Study description and baseline characteristics of the population enrolled in the extended forsteo® observational study (ExFOS)

ba0001pp430 | Osteoporosis: treatment

First in man study of a novel and highly selective cathepsin K inhibitor miv-711 – safety, pharmacokinetics and pharmacodynamics of single ascending oral doses in healthy subjects

ba0001pp431 | Osteoporosis: treatment

Bisphosphonate treatment of painful vertebral fractures due to osteoporosis in five boys with Duchenne muscular dystrophy

ba0001pp432 | Osteoporosis: treatment

Effects of a mutated sclerostin peptide on bone and lean mass in mice

ba0001pp433 | Osteoporosis: treatment

Denosumab is associated with progressive improvements in hip cortical mass and thickness

ba0001pp434 | Osteoporosis: treatment

Bone histology and histomorphometry: effects of 5 years of denosumab in the FREEDOM Extension

ba0001pp435 | Osteoporosis: treatment

Denosumab's dynamic CTX profile is maintained over 6 years of treatment: first 3 years of the FREEDOM extension study

ba0001pp436 | Osteoporosis: treatment

Bone mineral density changes in patients with prior fracture suboptimally treated with a bisphosphonate: results from denosumab (DMAb)/ibandronate and DMAb/risedronate trials

ba0001pp437 | Osteoporosis: treatment

The spatial relationship between bone formation and bone resorption in healthy and ovariectomized mice treated with PTH, bisphosphonate or mechanical loading

ba0001pp438 | Osteoporosis: treatment

Optimizing fracture prevention: the fracture liaison service, an observational study

ba0001pp439 | Osteoporosis: treatment

The direct and indirect costs of an osteoporotic fracture: a prospective evaluation of elderly patients with a clinical fracture

ba0001pp440 | Osteoporosis: treatment

Strontium potently inhibits mineralisation in bone-forming osteoblast cultures while osteoclast formation from marrow mononuclear cells is moderately reduced

ba0001pp441 | Osteoporosis: treatment

Reducing the risk of hypocalcaemia with parenteral antiresorptive therapies: an audit

ba0001pp442 | Osteoporosis: treatment

Design of a prospective observational study to evaluate persistence and adherence during denosumab treatment, and patient characteristics in postmenopausal women with osteoporosis in routine clinical practice

ba0001pp443 | Osteoporosis: treatment

Zoledronic acid vs alendronate in the management of osteoporosis

ba0001pp444 | Osteoporosis: treatment

Correction of vitamin D deficiency in women with postmenopausal osteoporosis

ba0001pp445 | Osteoporosis: treatment

Effectiveness of the active metabolite of vitamin D in the treatment of postmenopausal osteoporosis

ba0001pp446 | Osteoporosis: treatment

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate– a randomized placebo-controlled trial

ba0001pp447 | Osteoporosis: treatment

Effects of sclerostin antibody and maintenance of new bone induced by sclerostin antibody in animal models

ba0001pp448 | Osteoporosis: treatment

Resolution of effects on bone turnover markers and bone mineral density after discontinuation of long-term bisphosphonate use

ba0001pp449 | Osteoporosis: treatment

Odanacatib treatment reduces remodeling- and stimulates modeling-based bone formation in adult OVX monkeys

ba0001pp450 | Osteoporosis: treatment

Transdermal delivery of BA058, a novel analog of hPTHrP (1-34), with a short wear time patch in preclinical and clinical studies

ba0001pp451 | Osteoporosis: treatment

Estimation of vertebral and femoral strength during the first three years of denosumab therapy using an alternative smooth non-linear finite element methodology

ba0001pp452 | Osteoporosis: treatment

Curbing our enthusiasm when prescribing strenuous exercises in osteopenia/osteoporosis, when fracture may occur under good intensions

ba0001pp453 | Osteoporosis: treatment

Factors influencing levels of bone resorption during denosumab dosing

Published by BioScientifica

Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more